These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282 [TBL] [Abstract][Full Text] [Related]
6. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024 [TBL] [Abstract][Full Text] [Related]
7. All that glitters is not prostate cancer: incidental finding of PSMA-avid meningioma. Haemels M; Jentjens S; Cleeren F; Sciot R; Lambert J; Van Laere K; Goffin K Hell J Nucl Med; 2020; 23(1):79-80. PubMed ID: 32222733 [TBL] [Abstract][Full Text] [Related]
8. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034 [TBL] [Abstract][Full Text] [Related]
9. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854 [TBL] [Abstract][Full Text] [Related]
10. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Kabasakal L; Demirci E; Nematyazar J; Akyel R; Razavi B; Ocak M; Aygun A; Obek C; Kural AR Nucl Med Commun; 2017 Feb; 38(2):149-155. PubMed ID: 27893589 [TBL] [Abstract][Full Text] [Related]
11. PSMA and FDG PET/CT Findings in Patient With Dedifferentiated Liposarcoma and Prostate Cancer Metastases. Liao X; Sun H; Chen X; Fan Y; Zhang J Clin Nucl Med; 2024 Jul; 49(7):652-654. PubMed ID: 38689438 [TBL] [Abstract][Full Text] [Related]
12. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study. Domachevsky L; Bernstine H; Goldberg N; Nidam M; Catalano OA; Groshar D Eur Radiol; 2020 Jan; 30(1):328-336. PubMed ID: 31332559 [TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer. Hinsenveld FJ; Wit EMK; van Leeuwen PJ; Brouwer OR; Donswijk ML; Tillier CN; Vegt E; van Muilekom E; van Oosterom MN; van Leeuwen FWB; van der Poel HG J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222 [TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
15. Ureteral Metastasis From Prostate Cancer: A PSMA PET Pitfall. Chaussé G; Skinnider B; Crook J; Black P; Abikhzer G; Probst S Clin Nucl Med; 2020 Sep; 45(9):689-691. PubMed ID: 32558720 [TBL] [Abstract][Full Text] [Related]
16. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT. Baumann R; Koncz M; Luetzen U; Krause F; Dunst J Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556 [TBL] [Abstract][Full Text] [Related]
17. Utility of Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853 [TBL] [Abstract][Full Text] [Related]
18. Abdominal Wall Desmoid Fibromatosis Mimics Sarcoma With Intense FDG Uptake on FDG PET/CT. Xu F; Liu ML; Pastakia B; Liu F Clin Nucl Med; 2015 Aug; 40(8):e423-5. PubMed ID: 25674878 [TBL] [Abstract][Full Text] [Related]